Antibody-drug conjugate (ADC) development involves many different elements requiring specialized capabilities during the manufacturing process. Given the complexity of their development and manufacturing, accelerating timelines becomes a pivotal success factor for the ADC market.

In this whitepaper, Thomas Rohrer, Senior Director of Technical Support Bioconjugates, delves into how integrating development and production activities within a single outsourcing partner can dramatically streamline ADC development timelines and mitigate risks. Read more

Overcoming ADC development and supply chain challenges 

ADC developers relying on a fragmented supply chain face a range of challenges associated with the intricacies of vendor management. With multiple suppliers to oversee, each specializing in a unique ADC component (antibody, linker, and payload), companies frequently wrestle with harmonizing quality controls, synchronizing timelines, and ensuring efficient communication among all entities. The absence of an integrated drug development service also exposes developers to potential inconsistencies in product quality. 

As each vendor enforces its distinct set of quality parameters, discrepancies can emerge, affecting the final ADC product's potency and safety. Moreover, aligning timelines among varied suppliers can evolve into a logistical conundrum, which may culminate in unforeseen production delays. The transportation and storage of ADC components pose another layer of complexity. Developers must navigate the logistical hurdles of receiving materials from different geographical locations, each presenting unique bottlenecks. The diverse storage prerequisites for distinct components, ranging from specific temperature controls to unique handling protocols, can further complicate the process, requiring heightened vigilance and resource allocation.